Click a link below to view the mailing archive as if it had been sent to you.
| 2024-01-31 12:15 | | Gilead’s Kite Gets FDA Approval for Faster CAR T Therapy Manufacturing and more... |
| 2024-01-31 00:15 | | As AstraZeneca gears up for courtroom showdown over IRA, Novo's case faces separate HHS rebuke and more... |
| 2024-01-30 12:15 | | Pfizer posts surprise 4th quarter profit, but key products miss on sales and more... |
| 2024-01-30 00:15 | | J&J, Merck CEOs to testify at Senate panel after Sanders’ subpoena threats and more... |
| 2024-01-29 12:15 | | AstraZeneca, Daiichi aim for first pan-tumor ADC approval and more... |
| 2024-01-29 00:15 | | How Masimo forced Apple to redesign its smartwatches and more... |
| 2024-01-27 00:15 | | After Padcev combo’s major triumph, Merck’s Keytruda delivers partial win in bladder cancer and more... |
| 2024-01-26 12:15 | | Check out the most effective pharma ads of 2023 and more... |
| 2024-01-26 00:15 | | Merck CEO refused to testify in Senate because he’s not an expert in drug pricing, Bernie Sanders says and more... |
| 2024-01-25 12:15 | | Saudi Arabia launches plan to become biotech hub by 2040 and more... |
| 2024-01-25 00:15 | | Lilly's Mounjaro dose in limited availability in US through next month and more... |
| 2024-01-24 12:15 | | Where Will CRISPR Therapeutics Be in 5 Years? and more... |
| 2024-01-24 00:15 | | Johnson & Johnson inks $700M deal to resolve talc consumer protection claims from 42 states and more... |
| 2024-01-23 12:15 | | Sickle Cell Gene Therapies Seen as Cost Effective Below $2M Threshold: Study and more... |
| 2024-01-23 00:15 | | Another big pharma competed for Karuna, submitting all-cash offer day before BMS deal announcement and more... |
| 2024-01-22 12:15 | | 6 Neuro Data Readouts to Watch in the First Half of 2024 and more... |
| 2024-01-22 00:15 | | New Wegovy TV Commercial Launched After Pause to Deal with High Demand and more... |
| 2024-01-19 12:15 | | FDA adds 'boxed warning' for Amgen's Prolia and more... |
| 2024-01-19 00:15 | | Then and Now: What’s Changed—and What Hasn’t—in Some Early Biopharma Hotbeds and more... |
| 2024-01-18 12:15 | | AbbVie’s Humira Maintains Market Dominance Amid Biosimilar Launches: Report and more... |
| 2024-01-18 00:15 | | Six Reasons Drug Prices Are So High in the U.S. and more... |
| 2024-01-17 12:15 | | IRA lawsuits will be vital test of US’ ability to regulate pharma market and more... |
| 2024-01-16 12:15 | | Merck (MRK) Keytruda Ok'd by FDA for Expanded Cervical Cancer Use and more... |
| 2024-01-15 12:15 | | Top 10 Clinical Trial Trends for 2024 and more... |
| 2024-01-12 12:15 | | JPM2024: IRA Favors Biologics Over Small Molecule Drugs and Hurts Innovation, Industry Analysts Say and more... |
| 2024-01-12 00:15 | | JPM2024: Cancer Biotech Executives Look Ahead to the Coming Year and more... |
| 2024-01-11 12:15 | | ‘Let The Good Times Roll Again’: VCs Confident in Biotech Activity for ’24 and more... |
| 2024-01-11 00:15 | | 13 Therapies Make Clarivate’s 2024 Drugs to Watch List and more... |
| 2024-01-10 12:15 | | JPM24, Day 3: Gene editors take the stage to talk business development, germline edits and more... |
| 2024-01-10 00:15 | | JPM 2024: Renewal is a common theme among pharma CEOs and more... |
| 2024-01-09 12:15 | | JPM24: Amgen CEO hopes to take a bite of competitive obesity market with unique approach and more... |
| 2024-01-09 00:15 | | Novartis in advanced talks to buy Cytokinetics and more... |
| 2024-01-08 12:15 | | JPM24, Day 1: Regeneron's Eylea misses analyst estimates; Moderna touts $6.7B in '23 sales and more... |
| 2024-01-08 00:15 | | After Pfizer's exit, UCB splits from industry trade group BIO and more... |
| 2024-01-05 12:15 | | Merck seeks GLP-1 drugs with benefits beyond weight loss - CEO and more... |
| 2024-01-04 12:15 | | Novo Nordisk, Eli Lilly's weight-loss drugs under FDA scrutiny for suicidal thoughts, hair loss and more... |
| 2024-01-04 00:15 | | Pfizer rings in New Year with hemophilia B gene therapy nod in Canada and more... |
| 2024-01-03 12:15 | | Goldman Sachs closes $650M fund aimed at biotechs and more... |
| 2024-01-03 00:15 | | FDA ends busy year with three drug rejections and more... |
| 2024-01-02 12:15 | | Biopharma Closes 2023 with Flurry of M&A Activity from AstraZeneca, BMS, Roche and more... |
